Stevanato Group S.p.A. (NYSE:STVN) Shares Acquired by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. boosted its position in Stevanato Group S.p.A. (NYSE:STVN) by 1,457.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,654 shares of the company’s stock after buying an additional 5,291 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Stevanato Group were worth $123,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in STVN. Mutual of America Capital Management LLC acquired a new stake in shares of Stevanato Group during the fourth quarter worth approximately $13,848,000. M&T Bank Corp acquired a new position in Stevanato Group during the 4th quarter worth $572,000. Wellington Management Group LLP increased its position in shares of Stevanato Group by 4.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,693,588 shares of the company’s stock worth $53,872,000 after purchasing an additional 115,050 shares during the last quarter. Jennison Associates LLC acquired a new stake in shares of Stevanato Group in the 4th quarter valued at about $20,239,000. Finally, Glenmede Trust Co. NA lifted its position in shares of Stevanato Group by 12.7% during the third quarter. Glenmede Trust Co. NA now owns 35,941 shares of the company’s stock worth $719,000 after purchasing an additional 4,050 shares during the last quarter.

Stevanato Group Trading Down 0.8 %

Shares of NYSE:STVN opened at €22.34 ($24.02) on Tuesday. The company has a 50 day moving average of €21.04 and a 200-day moving average of €20.59. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The firm has a market cap of $6.77 billion, a P/E ratio of 47.53, a P/E/G ratio of 7.18 and a beta of 0.60. Stevanato Group S.p.A. has a twelve month low of €16.56 ($17.81) and a twelve month high of €33.49 ($36.01).

Stevanato Group (NYSE:STVN) last issued its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The firm had revenue of €352.68 million during the quarter, compared to analyst estimates of €346.26 million. As a group, analysts anticipate that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. William Blair reissued an “outperform” rating on shares of Stevanato Group in a report on Friday, March 7th. Wolfe Research started coverage on Stevanato Group in a research report on Friday, December 13th. They set an “outperform” rating and a $28.00 price target on the stock. Bank of America lifted their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Morgan Stanley reissued an “equal weight” rating and set a $23.00 target price (down from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. Finally, UBS Group decreased their price target on shares of Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a report on Friday, March 7th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of €27.75 ($29.84).

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.